September 9, 2019 Clinical Research/Diagn. M&A, Partnerships PR/Corporate

Ground-breaking trial demonstrates potential of blood test which harnesses the power of the immune system to reduce late detection of lung cancer

9 September 2019, Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, welcomes the presentation of data today by Professor Frank Sullivan (Chief Investigator on the ECLS trial) which has demonstrated the potential of Oncimmune’s EarlyCDT® Lung test to reduce the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical diagnosis.... Read more

September 9, 2019 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor

Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered non-small cell lung cancer and thyroid cancer patients who may be suitable for LOXO-292, Lilly’s RET inhibitor CARLSBAD, Calif., Sept. 9, 2019 /PRNewswire/ — Thermo... Read more

September 6, 2019 Clinical Research/Diagn. Product Launch

European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer

Basel, 06 September 2019 European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer The approval of the new Tecentriq-based combination expands treatment options for people across Europe affected by non-squamous non-small cell lung cancer (NSCLC) Decision based on data showing that the Tecentriq plus... Read more

September 5, 2019 Clinical Research/Diagn.

New Study Reinforces Clinical Utility of Combining Tumor Mutation Burden and PD-L1 as Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy

New Study Reinforces Clinical Utility of Combining Tumor Mutation Burden and PD-L1 as Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy CARLSBAD, Calif., Sept. 5, 2019 /PRNewswire/ — Tumor mutational burden (TMB) has recently emerged as a potential biomarker to help guide ICI (immune checkpoint inhibitor) therapy. A new study published in The Journal of Pathology further establishes TMB’s... Read more

September 5, 2019 Clinical Research/Diagn. Life Science Tools M&A, Partnerships Microscopy

European Research Initiative Adopts PacBio Sequel II System to Solve Rare Diseases

MENLO PARK, Calif., Sept. 05, 2019 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that its Single Molecule, Real-Time (SMRT®) Sequencing technology has been selected by the European research program SOLVE-RD to help reveal the genetic mechanisms responsible for rare genetic... Read more

September 4, 2019 Clinical Research/Diagn. Mass Spectrometry Product Launch

Fluidigm Launches Imaging Mass Cytometry Immuno-Oncology Panel Kits and Advanced CyTOF Software at the 2019 World Molecular Imaging Congress (WMIC)

Fluidigm Showcases Immuno-Oncology Imaging Innovations at WMIC to Advance Translational and Clinical Cancer Research SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), the global leader in highly multiplexed single-scan tissue imaging, today announced the launch of three new Imaging Mass Cytometry™ Maxpar® Human Immuno-Oncology Panel Kits and an advanced CyTOF® Software solution at the World... Read more

September 3, 2019 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific Announces Collaboration to Develop Advanced Analytical Workflows for Clinical Laboratories

Thermo Fisher Scientific Announces Collaboration to Develop Advanced Analytical Workflows for Clinical Laboratories SAN JOSE, Calif., Sept. 3, 2019 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, and Cedars-Sinai, a leading nonprofit academic healthcare organization, have entered into a collaboration to develop a pathway to precision medicine through the development of robust,... Read more

September 3, 2019 Atomic Spectroscopy Clinical Research/Diagn.

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 03 September 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares... Read more

August 29, 2019 Clinical Research/Diagn. Licensing, IP, and Legal Product Launch

Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq

Basel, 29 August 2019 Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq This launch represents an important step in Roche’s personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicine Each year 300,000... Read more

August 21, 2019 Clinical Research/Diagn. Lab Top-10 Licensing, IP, and Legal

Clinical Study Published in Prenatal Diagnosis Further Validates PerkinElmer’s Vanadis Fully Automated NIPT Platform

CE-Marked Solution Gives Pregnant Women Widespread Access to Non-Invasive Prenatal Testing WALTHAM, Mass. – August 21, 2019 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that its Vanadis® fully automated non-invasive prenatal testing (NIPT) system has been validated in an external clinical study, titled “Clinical Validation of a... Read more